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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a 
disease characterized by a progressive airflow limitation. Soluble uro-
kinase-type plasminogen activator receptor (suPAR) is released from 
the membrane-bound plasminogen activator, and is positively corre-
lated with the activation of immune system.
Aims: Release of inflammatory mediators is increased in chronic obs-
tructive pulmonary disease (COPD), particularly during exacerbations. 
The objective of this study was to compare plasma levels of suPAR 
and serum levels of C-reactive protein (CRP) during exacerbation and 
stable periods in patients with COPD.
Study Design: Prospective clinical study.
Methods: The patients with COPD were divided into 3 groups for 
evaluations: those with stable COPD [SCOPD] (n= 54),  pre-treatment 
acute exacerbation COPD [AECOPD] (n= 53), and post-treatment AE-
COPD (n= 52). Plasma suPARand serum CRP levels were assessed for 
each patient.
Results: Whereas the increased serum CRP levels of the participants 
were 54.82±56.63 mg/l during acute exacerbation period, during the 
stable period it was 5.02±6.31 mg/l and statistically significant (p= 
0.0001). The suPAR level was 1.28±0.52ng/ml during the acute exa-
cerbation period vs.1.21±0.59ng/ml during the stable period, without 
a difference (p= 0.49). There was a statistically significant decrease 
in the CRP serum levels; yet, although not statistically significant a 
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Introduction
Chronic obstructivepulmonary disease (COPD) is 
a disease characterized by a progressive airflow 
limitation and recurrent acute exacerbations as-
sociated with an inflammatory response in lungs 
to the chronic inhalation of noxious particles and 
gases [1].
Exacerbations observed during the course of the 
disease are a major cause of morbidity and mortali-
ty. They have an impact on quality of life in patients 
with COPD, leading to hospitalizations to a consi-
derable extent [2].
A review of COPD epidemiology indicates 
that according to the World Health Organization 
(WHO) dataabout 600 million people suffer from 
COPD all over the world, with 2.3 million people 
dying each year because of COPD [3]. Furthermo-
re, COPD is currently the fourth leading cause of 
death among all others, and it is projected to be 
the third by 2020 [4] Genetic and environmental 
factors, inflammation and oxidative stress contri-
bute to development of COPD. Some inflammatory 
mediators such as monocyte-macrophages, CD8 
T-lymphocytes, neutrophils, eosinophils and inter-
leukin (IL)-8, leukotriene B4 (LTB4), tumor necrosis-
factor (TNF)-α are involved in COPD inflammation. 
The main source of pathological findings in COPD 
is the destructive and structural changes caused by 
inflammatory products. Any acute exacerbation of 
COPD leads to increased airway inflammation, and 
thus increased release of inflammatory mediators 
[5, 6].
C-reactive protein (CRP), the first acute phase 
reactant discovered, is detected in serum as early 
as four hours after the damage. 
Early and quick diagnosis of COPD exacerbationis 
very important, particularly in prevention of mortali-
ty. Therefore, CRP and procalcitonin are mainly used 
as biomarkers to determine COPD exacerbation and 
response. Recently, a new biomarker called suPAR 
(Soluble form of the urokinase-type plasminogen 
activator receptor) with significantly elevated levels 
in diseases such as sepsis and bacteremia has been 
identified [7-9].
Soluble urokinase-type plasminogen activator 
receptor (suPAR) is released from the membrane-
bound plasminogen activator, and is positively co-
rrelated with the activation of immune system. Nu-
merous studies on various infections, inflammatory 
diseases and cancer have shown increased systemic 
levels of suPAR [10-14]. However, the new biological 
marker, suPAR has not been studied in demonstra-
ting COPD exacerbation.
remarkable decrease was seen in the suPAR levels obtained before 
and after the management of exacerbations (p= 0.001 and p= 0.06 
respectively).
Conclusion: These results support the idea that suPAR, a novel 
biomarker, might be an important indicator if verified with further 
prospective studies in evaluating COPD exacerbations and treatment 
response like CRP used for decades.
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The aim of present study was to determine if 
suPAR, as a new biological marker, is as sensitive as 
CRP in the evaluation of COPD exacerbations and 
response.
Material Methods
The COPD patients who presented to the Chest 
Diseases Clinic between October 2012 and April 
2013 were divided into 3 groups; those with sta-
ble COPD [SCOPD] (n= 54), pre-treatment acute 
exacerbation COPD [AECOPD] (n= 53), and post-
treatment AECOPD (n= 52). AECOPD and post-
treatment AECOPD group consisted of the same 
patients; Yet, we had an exodus and thus one 
patient less. Presence of one or more symptoms 
such as increased amount of sputum, purulence, 
shortness of breath, chest tightness, and wheezing 
was considered an acute exacerbation [15, 16]. For 
SCOPD, patients were required not to have any 
acute exacerbation symptoms at least in a four-
week period. We excluded those who were youn-
ger than 40 years, and pregnant, had a non-COPD 
disease such as asthma-bronchiectasis-tuberculo-
sis, malignancy (pulmonary and non-pulmonary), 
chronic renal failure associated with increased 
serum level of CRP, chronic liver failure, collagen 
tissue disease, and cardiac diseases including vas-
culitis. All patients provided a detailed medical his-
tory including their smoking status and duration of 
disease; and their physical examination findings, 
chest X-rays and grades of dyspnea (according to 
the ATS dyspnea score) were evaluated;and respi-
ratory function tests, and arterial blood gas para-
meters were assessed.
Measurement of serum CRP level;Peripheral ve-
nous blood samples were obtained using EDTA-
containing blood collection tubes. Then, the sam-
ples were centrifuged at 3000 rpm for 5 min to 
separate the plasma. The plasma was stored at 
-80oC in a deep freezer before performing the CRP 
assays. CRP (Cardio Phase CRP, Siemens Healthcare 
Daignostics Products GmbH, Hamburg, Germany) 
assays were performed by using a fully-automated 
nephelometric assay system (BN II Seimens Health-
care Diagnostics Inc. Tarrytown, NY, USA). The refe-
rence range for CRP was 0.00-5.00 mg/L in healthy 
individuals depending on the assay method used.
The plasma samples of patients were stored at 
80oC in a deep freezer for measurement of suPAR 
levels like CRP. For suPAR assays, a micro ELISA reac-
tive (Receptor (PLAUR/uPAR) ELISA Kit, Hangzhou 
Eastbiopharm Co. Ltd. Hangzhou, PRC) and a micro 
plate reader (Biotek ELx 800, BioTek Instrumenta-
tions, Inc, Winooski, VT, USA) were used. 
The study protocol was approved by the local 
ethics committee. A written informed consent was 
obtained from all subjects. 
Statistical Analyses
All statistical analyses were performed using SPSS 
statistical package (version 15 for Windows, SPSS; 
Chicago, Ill., USA). Descriptive analyses were per-
formed for all variables. The association between 
two quantitative variables was evaluated with 
Pearson’s correlation coefficient. The results were 
expressed as means and standard deviations for 
quantitative variables, and as frequencies for cate-
gorical findings. To compare means of two inde-
pendent groups, student’s t test was used, while 
nonparametric data were analyzed with the Mann-
Whitney U test. The Kruskal-Wallis test was used 
to compare nonparametric data of several groups. 
To identify the differences between the aforemen-
tioned markers, we performed an unadjusted and 
adjusted regression analysis and a logistic regres-
sion analysis. The level of statistical significance 
was taken as p<0.05. 
Results
The patients with COPD were divided into 3 groups 
for evaluations: The mean age of groups were 
SCOPD (62.12±9.26 years), pre-treatment AECOPD 
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(66.13±10.34 years), and post-treatment AECOPD 
(66.30±10.34 years). The demographic characteris-
tics of groups are shown in Table 1. 
All patients were male. CRP and suPAR were 
measured in all groups. 
The suPAR levels for SCOPD was 1.21±0.59, 
for AECOPD was 1.28±0.52, and post-treatment 
AECOPD 1.02±0.41 (Table 2-3). Accordingly, in 
the AECOPD group the suPAR level was eleva-
ted during exacerbations compared to SCOPD; 
yet without a statistical significance (p= 0,49). In 
addition, post-treatment suPAR levels were lower 
than pre-treatment in the AECOPD group. Howe-
ver the difference was not statistically significant 
(p= 0,06).
CRP levels of SCOPD group was 5.02±6.31, of 
pre-treatment AECOPD 54.82±56.63, and post-
treatment AECOPD 5.93±5.20. The CRP levels of 
pre-treatment AECOPD levels were higher than 
both groups and statistically significant (p<0,05) 
(Table 2-3). 
The area under curve (AUC) value for CRP was 
0.88, (p= 0.001) and cut off value was 7,67. Addi-
tionally, sensitivity was 84.9% and specifity was 
85.0%. On the other hand, the AUC value for su-
PAR was 0.621 (p= 0.01) (Figure 1).
According to Spearman's correlation analysis, the 
correlation between CRP and suPAR was r= 0.147 
(p= 0.06). Therefore, it was concluded that suPAR 
was not as sensitive as CRP as a biomarker of exa-
cerbations in patients with COPD (Figure 2).
Table 1.  Demographic characteristics of groups.
COPD 
(n=54)
AECOPD 
(n=53)
After 
Treatment 
COPD
 (n=52)
Age 62,12+9,26 66.13+10,34 66,30+10,34
Fev1 43,24+14,29 36,07+15,00 42,11+17,62
pO2 64,70+17,03 55,18+12,06 62,64+17,63
Smoking
(pack/years)
44,51+34.57 39.50+33.54 38.92+32.46
mMRC
(dispnea score)
2.56+1.00 4.00+1.00 3.21+1.17
SCOPD:  Stable chronic obstructive pulmonary disease.
AECOPD:  Acute exacerbation chronic obstructive 
pulmonary disease 
Fev1: Force expiratory volume second 1
mMRC:  Modified medical research council
Table 2.  CRP and suPAR results between SCOPD 
and AECOPD.
SCOPD 
(n=54)
AECOPD 
(n=53)
P value
CRP mg/L 5,02±6,31 54,82±56,63 0.0001
suPAR ng/ml 1,21±0,59 1,28±0,52 0.49
p<0.05 statistically significant
Table 3.  CRP and suPAR results between AECOPD 
and After Treatment COPD.
AECOPD 
(n=53)
After 
Treatment 
COPD (n=52)
P value
CRP mg/L 54,82±56,63 5,93±5,20 0.001
suPAR ng/ml 1,28±0,52 1,020±0,41 0.06
p<0.05 statistically significant
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Discussion
In the present study, plasma suPAR levels of AECO-
PD patients were higher than the SCOPD group; yet 
this difference is not statistically signifcant. Likewise 
pre-treatment plasma suPAR levels of AECOPD pa-
tients was higher than post-treatment AECOPD; yet 
without statistically significant. Backes et al. showed 
that diagnostic value of suPAR is low in demonstra-
ting inflammation, which is also consistent with our 
findings [17]. Regarding the suPAR levels of SCOPD 
patients throghout an inflammation there is, acor-
ding to our best knowledge, only one report in the 
current literature [18]. In that study, the plasma su-
PAR levels of the SCOPD patients were signicantly 
higher than that of the healthy controls indicating 
the these findings might reflect the inlammatory 
process in SCOPD.
Additionally, Gustafsson et al. compared the 
suPAR levels in patients with severe sepsis with 
other inflammatory markers, and showed that 
suPAR can be used in predicting severity and 
mortality of sepsis [19]. Similarly, Donadello et 
al.indicated that suPAR can be used as prognostic 
biomaker in sepsis [20]. More than 150 biological 
markers have been studied in patients with sepsis, 
however most of them are not routinely used in 
daily practice [21].
In the present study, CRP levels of both SCOPD 
and post-treatment AECOPD were lower compared 
to pre-treatment AECOPD in line with the reduced 
inflammation. This difference in the CRP levels of 
both groups were statistically significant. 
In line with the present study, Hurst et al. showed 
that CRP is the most practical and best known bio-
marker in detecting COPD exacerbations [22].
This is the first pilot study on suPAR concentra-
tions in patients with SCOPD and AECOPD.
Limitations of the study: The limitations of our 
study is the lack of a comparison with healthy con-
trols, limited patient series, and that all participants 
were male. 
Figure 1.  Results for ROC analysis of CRP and 
suPAR levels in COPD patients as mar-
kers of exacerbations (0.888 and 0.621, 
respectively).
Figure 2.  Association between levels of CRP and 
suPAR (p=0.06).
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In conclusion, we believe that the new biomarker, 
suPAR is not as sensitive as CRP in demonstrating 
COPD exacerbations, and its use as a marker of 
exacerbation may be limited in patients with COPD. 
Future studies with larger patient series and with a 
control group consisting of healthy patients may re-
flect the inflammatory process in AECOPD patients 
based on plasma suPAR levels. Yet, before it can be 
used like CRP further clinical studies including more 
patients to evaluate suPAR in patients with COPD 
are needed. 
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